Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Yishai Ofran, MD, Ronit Leiba, Dina Rosenberg, Israel Henig, MD, Dana Yehudai-Ofir, MD, Nuhad Haddad, MD, Riva Fineman, MD, Avraham Frisch, MD, Doaa Okasha, MD, Yariv Carasso, MD, Tsila Zuckerman, MD, Nurit Horesh, MD

Blood (2019) 134 (Supplement_1): 2603.

https://doi.org/10.1182/blood-2019-126553

Published: 2019

Journal Articles

Prognosis of Patients with Standard- or Intermediate-Risk Acute Myeloid Leukemia Presenting with Residual Disease after One Induction Cycle Is Improved If Remission Is Achieved Following Re-Induction Given By Day 14 Compared to Second-Line Therapy Given 24-40 Days after Induction

Avraham Frisch, MD, Ronit Leiba, MSc, Chezi Ganzel, Tsila Zuckerman, MD, Nuhad Haddad, MD, Riva Fineman, MD, Yishai Ofran, MD

Blood (2016) 128 (22): 3999.

https://doi.org/10.1182/blood.V128.22.3999.3999

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience

Ofrat Beyar-Katz, MD, Israel Henig, MD, Dana Yehudai, MD, Nov Yuval, MSc, Riva Fineman, MD, Nuhad Haddad, MD, Yishai Ofran, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2016) 128 (22): 5819.

https://doi.org/10.1182/blood.V128.22.5819.5819

Published: 2016

Journal Articles

Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients

Tsila Zuckerman, MD, Ruth Ben Yakar, PhD, Stela Gengrinovitch, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Olga Nudelman, MD, Nuhad Haddad, MD, Martin S Tallman, MD, Jacob M. Rowe, MD

Blood (2015) 126 (23): 3810.

https://doi.org/10.1182/blood.V126.23.3810.3810

Published: 2015

Journal Articles

Anti-HLA Antibodies in Neonatal Alloimmune Thrombocytopenia - Is There Any Clinical Significance?

Lilach Bonstein, PhD, Nardeen Atweh, BSc, Nuhad Haddad, MD, Yariv Fruchtman, MD

Blood (2015) 126 (23): 4647.

https://doi.org/10.1182/blood.V126.23.4647.4647

Published: 2015

Journal Articles

High Incidence of Alloimmunization to Platelets and Platelet Transfusion Refractoriness during Induction Therapy in Patients Diagnosed with Acute Myeloid Leukemia

Lilach Bonstein, PhD, Roy Lauterbach, MD, Nuhad Haddad, MD

Blood (2015) 126 (23): 3484.

https://doi.org/10.1182/blood.V126.23.3484.3484

Published: 2015

Journal Articles

Stable Blood Group Chimerism in Recipients of ABO Incompatible Allogeneic Stem Cell Transplantation

Ami Glik, MD, Lilach Bonstein, PhD, Nardeen Atwah, BSc, Eti Ganon-Elazar, PhD, Israel Henig, MD, Nuhad Haddad, MD, Riva Fineman, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2014) 124 (21): 1553.

https://doi.org/10.1182/blood.V124.21.1553.1553

Published: 2014

Journal Articles

Semaphorin 3A Expression on Donor and Recipient Regulatory Cells: A Novel Pre-Transplant Biomarker Predicting the Development of Acute Graft-Versus-Host Disease

Zahava Vadas, MD PhD, Eti Ganon-Elazar, PhD, Yuval Nov, PhD, Israel Henig, MD, Dina Attias, MD, Nuhad Haddad, MD, Riva Fineman, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2014) 124 (21): 3935.

https://doi.org/10.1182/blood.V124.21.3935.3935

Published: 2014

Journal Articles

Female Donor Allografts Have a Higher CD3 Content Than Male Donor Allografts: Potential Impact On Transplantation Outcomes in Male Recipients

Moshe Yeshurun, MD, Ron Ram, MD, Ofer Shpilberg, MD, MPH, Corina Herscovici, MD, Liat Vidal, MD, Tsila Zuckerman, MD, Nuhad Haddad, MD, Jacob M Rowe, MD, Ronit Yerushalmi, Arnon Nagler, MD, Avichai Shimoni

Blood (2012) 120 (21): 587.

https://doi.org/10.1182/blood.V120.21.587.587

Published: 2012

Journal Articles

Post-Engraftment Persistent Leukocytosis May Be An Independent Poor Prognostic Factor in Allogeneic Stem Cell Transplant Patients

Nuhad Haddad, MD, Riva Fineman, MD, Tsila Zuckerman, MD, Jacob M. Rowe, MD

Blood (2011) 118 (21): 4574.

https://doi.org/10.1182/blood.V118.21.4574.4574

Published: 2011

Journal Articles

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Eldad Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Menachem Ben-Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Nuhad Haddad, MD, Hanna Rosenbaum, MD, Riva Fineman, MD, Odelia Goor, MD, Diana Libster, MD, Zeev Blumenfeld, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2009) 114 (22): 1552.

https://doi.org/10.1182/blood.V114.22.1552.1552

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies – A Curative Approach When Performed as a Primary Therapeutic Modality: A Single Center Experience.

Ronit Elhasid, MD, Irina Zaidman, MD, Abdalla Khalil, MD, Tsila Zuckerman, MD, Nuhad Haddad, MD, Tamar Katz, Ph.D, Myriam Ben Arush, MD, Jacob M. Rowe, MD

Blood (2009) 114 (22): 1144.

https://doi.org/10.1182/blood.V114.22.1144.1144

Published: 2009

Journal Articles

Successful Long- Term Outcome and Chimeric Status Following Allogeneic Stem Cell Transplantation for Non-Malignant Disorders Using Moderate T Cell Depletion with No Post Transplant Gvhd Prophylaxis.

Ronit Elhasid, MD, Irina Zaidman, MD, Khalil Abdalla, MD, Miriam Ben-Arush, MD, Nuhad Haddad, MD, Tsila Zuckerman, MD, Osnat Gidoni, Dina Rubin, Rina Katz, Shimon Polack, MD, Yair Reisner, Ph.D, Jacob M. Rowe, MD

Blood (2008) 112 (11): 3292.

https://doi.org/10.1182/blood.V112.11.3292.3292

Published: 2008

Journal Articles

Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival.

Tsila Zuckerman, MD, Tamar Katz, PhD, Nuhad Haddad, MD, Riva Fineman, MD, Irit Avivi, MD, Eldad J. Dann, MD, Dvora Sahar, PhD, Ana Oliven, MSc, Ety Hertz, Yishay Ofran, MD, Luiza Akria, MD, Michal Markovitz, Tal Faibish, MSc, Jacob M. Rowe, MD

Blood (2006) 108 (11): 318.

https://doi.org/10.1182/blood.V108.11.318.318

Published: 2006

Journal Articles

CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.

Tsila Zuckerman, MD, Shani Ben Harush, MD, Irit Avivi, MD, Israel Gavish, MD, Nuhad Haddad, MD, Riva Fineman, MD, Eldad Dann, MD, Ron Hoffman, MD, Benjamin Brenner, MD, Jacob M. Rowe, MD, Eli Zuckerman, MD

Blood (2004) 104 (11): 1138.

https://doi.org/10.1182/blood.V104.11.1138.1138

Published: 2004

Journal Articles

Extracorporeal Photopheresis (ECP) for Acute and Chronic GVHD, a Report of 56 Patients Treated in a Single Institution.

Eldad J. Dann, MD, Alla Badian, MD, Tselestina Stravets, MD, Elena Kertsman, Irit Avivi, MD, Ronit Elhasid, MD, Nuhad Haddad, MD, Riva Fineman, MD, Tsila Zuckerman, MD, Ana Oliven, Lilah Bonstein, PhD, Jacob M. Rowe, MD

Blood (2004) 104 (11): 5106.

https://doi.org/10.1182/blood.V104.11.5106.5106

Published: 2004

NARROW

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Prognosis of Patients with Standard- or Intermediate-Risk Acute Myeloid Leukemia Presenting with Residual Disease after One Induction Cycle Is Improved If Remission Is Achieved Following Re-Induction Given By Day 14 Compared to Second-Line Therapy Given 24-40 Days after Induction

Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience

Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients

Anti-HLA Antibodies in Neonatal Alloimmune Thrombocytopenia - Is There Any Clinical Significance?

High Incidence of Alloimmunization to Platelets and Platelet Transfusion Refractoriness during Induction Therapy in Patients Diagnosed with Acute Myeloid Leukemia

Stable Blood Group Chimerism in Recipients of ABO Incompatible Allogeneic Stem Cell Transplantation

Semaphorin 3A Expression on Donor and Recipient Regulatory Cells: A Novel Pre-Transplant Biomarker Predicting the Development of Acute Graft-Versus-Host Disease

Female Donor Allografts Have a Higher CD3 Content Than Male Donor Allografts: Potential Impact On Transplantation Outcomes in Male Recipients

Post-Engraftment Persistent Leukocytosis May Be An Independent Poor Prognostic Factor in Allogeneic Stem Cell Transplant Patients

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies – A Curative Approach When Performed as a Primary Therapeutic Modality: A Single Center Experience.

Successful Long- Term Outcome and Chimeric Status Following Allogeneic Stem Cell Transplantation for Non-Malignant Disorders Using Moderate T Cell Depletion with No Post Transplant Gvhd Prophylaxis.

CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.

Extracorporeal Photopheresis (ECP) for Acute and Chronic GVHD, a Report of 56 Patients Treated in a Single Institution.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only